iTeos Therapeutics
ITOS
#5000
Rank
$0.77 B
Marketcap
$21.72
Share price
-2.38%
Change (1 day)
-38.52%
Change (1 year)

P/E ratio for iTeos Therapeutics (ITOS)

P/E ratio as of January 2023 (TTM): 5.27

According to iTeos Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 5.27482. At the end of 2021 the company had a P/E ratio of 7.83.

P/E ratio history for iTeos Therapeutics from 2020 to 2022

PE ratio at the end of each year

Year P/E ratio Change
20217.83-167.88%
2020-11.5

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-2.64-150.06%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.